Guggenheim Capital LLC Lowers Holdings in Natera, Inc. (NASDAQ:NTRA)

Guggenheim Capital LLC reduced its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 21.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,917 shares of the medical research company's stock after selling 9,250 shares during the period. Guggenheim Capital LLC's holdings in Natera were worth $5,211,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Natera by 7.7% in the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after purchasing an additional 879,463 shares during the last quarter. JPMorgan Chase & Co. grew its position in Natera by 43.7% in the fourth quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock worth $1,060,836,000 after buying an additional 2,036,396 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Natera by 15.7% during the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after acquiring an additional 439,778 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Natera by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock worth $355,809,000 after acquiring an additional 142,201 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of Natera by 40.0% in the 4th quarter. Franklin Resources Inc. now owns 1,538,875 shares of the medical research company's stock worth $243,604,000 after acquiring an additional 439,540 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Natera

In other news, CFO Michael Burkes Brophy sold 946 shares of the business's stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $171.98, for a total value of $162,693.08. Following the transaction, the chief financial officer now owns 109,474 shares in the company, valued at $18,827,338.52. The trade was a 0.86 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 13,685 shares of the company's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $165.87, for a total value of $2,269,930.95. Following the completion of the transaction, the chief executive officer now owns 253,944 shares of the company's stock, valued at $42,121,691.28. This trade represents a 5.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 199,194 shares of company stock valued at $30,646,524. 7.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research analyst reports. Morgan Stanley upped their price target on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Piper Sandler raised their target price on Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 4th. Canaccord Genuity Group reiterated a "buy" rating and set a $180.00 price target on shares of Natera in a report on Wednesday, February 26th. Barclays reduced their price objective on Natera from $200.00 to $160.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Finally, Sanford C. Bernstein upped their target price on Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Natera has an average rating of "Moderate Buy" and a consensus price target of $175.76.

Natera Price Performance

Shares of NASDAQ NTRA traded up $5.33 during mid-day trading on Wednesday, reaching $149.95. The company had a trading volume of 216,593 shares, compared to its average volume of 1,377,156. The business's 50-day simple moving average is $149.13 and its 200 day simple moving average is $153.04. The firm has a market cap of $20.27 billion, a price-to-earnings ratio of -85.20 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a one year low of $87.20 and a one year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.